It should explain why semaglutide is medically necessary for your specific case, reference your diagnosis codes and comorbidities, cite the clinical trial evidence (STEP 1 showed 14.9% mean weight loss, NEJM 2021
eGFR, estimated glomerular filtration rate as calculated by use of the formula: men (mL/min/1.73m 2 ) = 194Cr-1.094 age -0.287
All three showed benefits of semaglutide on kidney function, with SMART being the most directly relevant to Wegovy users with CKD because it used the Wegovy dose in the right population
BI 456906: discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy
Patients should be monitored for signs of inadequate nutritional intake, particularly elderly patients or those with low baseline body weight, as determined relevant by the prescribing clinician
10.2337/diaspect.27.2.100 7 DrostenMH